These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 20029816)

  • 21. Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana.
    Moyo S; Gaseitsiwe S; Zahralban-Steele M; Maruapula D; Nkhisang T; Mokaleng B; Mohammed T; Ditlhako TR; Bareng OT; Mokgethi TP; van Widenfelt E; Pretorius-Holme M; Mine MO; Raizes E; Yankinda EK; Wirth KE; Gaolathe T; Makhema JM; Lockman S; Essex M; Novitsky V
    AIDS; 2019 May; 33(6):1073-1082. PubMed ID: 30946161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug resistance mutations during structured interruptions of HAART in two HIV-1-infected children.
    Palacios-Saucedo GC; Rivera-Morales LG; Vázquez-Guillén JM; Sánchez LM; Ramírez TJ; Briones E; Ortiz-López R; Vázquez CA; Rodríguez-Padilla C
    Curr HIV Res; 2011 Apr; 9(3):154-9. PubMed ID: 21457133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine/emtricitabine/tenofovir DF or efavirenz/emtricitabine/tenofovir DF in the STaR study (GS-US-264-0110).
    Porter DP; Kulkarni R; Fralich T; Miller MD; White KL
    J Acquir Immune Defic Syndr; 2014 Mar; 65(3):318-26. PubMed ID: 24525469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV type 1 virological response and prevalence of HIV type 1 drug resistance among patients receiving antiretroviral therapy, Shandong, China.
    Zhang J; Kang D; Lin B; Sun X; Fu J; Bi Z; Nkengasong JN; Yang C
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1658-65. PubMed ID: 22563717
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug resistance-associated genotypic alterations in the pol gene of HIV type 1 isolates in ART-naive individuals in North India.
    Arora SK; Gupta S; Toor JS; Singla A
    AIDS Res Hum Retroviruses; 2008 Feb; 24(2):125-30. PubMed ID: 18240959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy.
    Vergne L; Kane CT; Laurent C; Diakhaté N; Gueye NF; Gueye PM; Sow PS; Faye MA; Liégeois F; Ndir A; Lanièce I; Peeters M; Ndoye I; Mboup S; Delaporte E
    AIDS; 2003 Jul; 17 Suppl 3():S31-8. PubMed ID: 14565607
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High level of HIV-1 drug resistance mutations in patients with unsuppressed viral loads in rural northern South Africa.
    Etta EM; Mavhandu L; Manhaeve C; McGonigle K; Jackson P; Rekosh D; Hammarskjold ML; Bessong PO; Tebit DM
    AIDS Res Ther; 2017 Jul; 14(1):36. PubMed ID: 28750647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.
    Saravanan S; Vidya M; Balakrishnan P; Kantor R; Solomon SS; Katzenstein D; Kumarasamy N; Yeptomi T; Sivamalar S; Rifkin S; Mayer KH; Solomon S
    Clin Infect Dis; 2012 Apr; 54(7):995-1000. PubMed ID: 22323567
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy of anti-HIV treatment and drug-resistance mutations in some parts of China].
    Han XX; Zhang M; Cui WG; Liu BG; Wang Yn; Zhang ZN; Liu J; Geng WQ; Diao YY; Dai D; Jiang YJ; Shang H
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):760-4. PubMed ID: 15949383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for antiretroviral drug resistance among treatment-naive human immunodeficiency virus type 1-infected individuals in Lebanon.
    Mokhbat JM; Melhem NM; El-Khatib Z; Zalloua P
    J Infect Dev Ctries; 2014 Mar; 8(3):339-48. PubMed ID: 24619266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. Swiss HIV Cohort Study.
    Khanna N; Klimkait T; Schiffer V; Irigoyen J; Telenti A; Hirschel B; Battegay M
    AIDS; 2000 May; 14(7):791-9. PubMed ID: 10839586
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.
    Gupta A; Saple DG; Nadkarni G; Shah B; Vaidya S; Hingankar N; Chaturbhuj D; Deshmukh P; Walshe L; Hudelson SE; James M; Paranjape RS; Eshleman SH; Tripathy S
    AIDS Res Hum Retroviruses; 2010 Jan; 26(1):25-31. PubMed ID: 20063995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir.
    Villabona-Arenas CJ; Eymard-Duvernay S; Aghokeng A; Guichet E; Toure-Kane C; Bado G; Koulla-Shiro S; Delaporte E; Ciaffi L; Peeters M
    AIDS Res Hum Retroviruses; 2018 Jun; 34(6):477-480. PubMed ID: 29575909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differences in the integrase and reverse transcriptase transmitted resistance patterns in Northern Poland.
    Parczewski M; Leszczyszyn-Pynka M; Urbańska A
    Infect Genet Evol; 2017 Apr; 49():122-129. PubMed ID: 28017912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.